ORGO Q1 2023 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$108M+10.8% YoY

Gross Profit

$81M75.3% margin

Operating Income

-$4M-3.7% margin

Net Income

-$3M-2.8% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-6.8%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$446M

Total Liabilities

$182M

Stockholders' Equity

$264M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$108M	$97M	+10.8%
Gross Profit	$81M	$72M	+12.5%
Operating Income	-$4M	-$128,000	-3025.8%
Net Income	-$3M	-$913,000	-225.2%

Revenue Segments

Advanced Wound care

$101M94%

Surgical and Sports Medicine

$7M6%